IBG-AUTOMATION GMBH

Their core work

IBG-Automation is a German automation SME specializing in modular assembly systems for industrial manufacturing. Their flagship product, iPROCELL, is a reconfigurable cell-based assembly concept designed to give manufacturers flexibility without sacrificing throughput. They pursued EU funding specifically to validate iPROCELL commercially — suggesting a product-driven company focused on bringing an internal innovation to market. Based in Neuenrade (Sauerland, NRW), they operate in a region with deep industrial manufacturing roots, likely serving automotive and mechanical engineering supply chains.

What they specialise in

How they've shifted over time

IBG-Automation's H2020 participation spans only 2016–2020 and is entirely focused on a single product — iPROCELL — making it impossible to observe a genuine shift in technical focus. The trajectory visible here is not about changing expertise, but about scaling conviction: they first validated the concept with a small Phase 1 grant, then committed fully to commercial rollout under Phase 2. This is a classic SME Instrument progression, not a research arc.

Their EU activity was a single focused commercialization push for one product; future collaboration potential depends entirely on whether iPROCELL reached the market and whether they have pursued further R&D since 2020.

How they like to work

IBG-Automation coordinated both of their EU projects independently — a strong signal that they are self-directed and comfortable leading grant processes without academic or large-industry partners doing the heavy lifting. With only 2 unique consortium partners across both projects and collaboration limited to Germany, they operate in very tight, trusted networks rather than broad European consortia. For a potential partner, this means a focused, low-bureaucracy collaboration, but also limited experience navigating multi-country project dynamics.

IBG-Automation's EU network is minimal — 2 unique partners, all within Germany. This reflects the nature of the SME Instrument, which is designed for single-company commercial validation rather than collaborative research consortia.

What sets them apart

IBG-Automation is notable for being a pure-product SME that used EU funding as a commercialization tool rather than a research tool — their entire H2020 track record is the same product moving through Phase 1 to Phase 2. For a consortium builder, they bring a market-tested assembly automation product and a demonstrated ability to lead SME Instrument projects. The risk is that their EU engagement appears to have ended in 2020, and there is no publicly visible sign of broader R&D activity beyond iPROCELL.

Highlights from their portfolio

• iPROCELL
  The Phase 2 SME Instrument grant of €1.2M represents a significant EU endorsement of the commercial viability of IBG-Automation's modular assembly concept, making it the defining project in their portfolio.
• iProcell
  The Phase 1 feasibility study (€50k) is notable as the entry point that unlocked the larger Phase 2 award — demonstrating a disciplined, staged approach to EU funding that few SMEs execute successfully.